Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Genome editing (also called gene editing) is a group of technologies that give scientists the ability to change an organism's DNA. These technologies allow genetic material to be added, removed or altered at particular locations in the genome. Several approaches to genome editing have been developed. A recent one is known as CRISPR-Cas9, which is short for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9. The CRISPR-Cas9 system has generated a lot of excitement in the scientific community because it is faster, cheaper, more accurate and more efficient than other existing genome editing methods. Moreover, CRISPR technology is a simple yet powerful tool for editing genomes. It allows researchers to easily alter DNA sequences and modify gene function. Its many potential applications include correcting genetic defects, treating and preventing the spread of diseases and improving crops. However, its promise also raises ethical concerns. In addition, CRISPR gene editing technique is currently used in cell and animal models. It has enormous potential in complex disorders such as hemophilia, cystic fibrosis, heart disease, sickle cell disease, cancer, human immunodeficiency virus (HIV) infection.
The CRISPR genome editing market is driven by major factors such as increasing disease burden across the globe, rising demand for synthetic genes and advancement in technologies in molecular biology field. In addition, huge investments in research and development is also the factor that is raising the growth of the CRISPR genome editing market globally. However, factor such as ethical issues concerning to misuse of genome editing and insufficient awareness & availability of other gene editing tools are impeding the CRISPR genome editing market growth.
The CRISPR genome editing market is classified into by applications, end-user, and geography
Various applications were studied into the CRISPR genome editing market report such as genome editing, genetic engineering, gene library, human stem cells and others. Moreover, other applications include genetically modified crops and organisms, cell line engineering. The human stem cells segment is anticipated increase significantly, owing to the factors such as growing industry focus on stem cell research, increasing global awareness about stem cell therapies and rising funding from governments and private organizations.
Based on end-user, the CRISPR genome editing market is bifurcated into biotechnology companies, pharmaceutical companies and others. Likewise, others include academic research centers, research institutes etc. Among this the increasing prevalence of infectious diseases and cancer are driving the research and development activities and innovations worldwide; this is anticipated to drive the demand for genome editing in biotechnology & pharmaceutical companies in the next few years.
The CRISPR genome editing market report is studied across the key countries of North America, Europe, Asia Pacific and Rest of the World. Due to huge investments in genome editing research and development, well-developed healthcare infrastructure, and technological advancements, the North America region is projected to witness the largest market share in 2018. However, the Aisa pacific region is expected to grow at a highest CAGR during the forecast period, owing to the Increasing government fund for research and development, increasing lifestyle-related disorders and rising disposable income.
Some of the major players operating in the CRISPR genome editing market includes Editas Medicine, Horizon Discovery PLC., CRISPR Therapeutics AG, Genscript, Sangamo Biosciences, Inc., Caribou Biosciences, Inc., Lonza Group AG, Transposagen Biopharmaceuticals, Integrated DNA Technologies, New England Biolabs Inc, Origene Technologies Inc., Thermo Fisher Scientific, Sigma-Aldrich Precision Biosciences, Cellectis, Intellia Therapeutics, Inc. and Novartis AG. New product launches, research and development and mergers & acquisitions are the key strategies adopted by market players to ensure their growth in the market.
December 2018: Intellia Therapeutics, Inc., a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced an expansion of its existing cell therapy collaboration with Novartis, to include the ex vivo development of innovative cell therapies using certain ocular stem cells.
August 28, 2018: Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, announced that is has entered into a collaboration with a global pharma partner to co-develop and apply a novel cutting-edge research tool for target identification and validation.
January 2015: Novartis announced that it has signed collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology and Caribou Biosciences for the development of drug discovery tools.
The CRISPR genome editing market is classified into by applications, end-user, and geography. Various applications were studied into the CRISPR genome editing market report such as genome editing, genetic engineering, gene library, human stem cells and others. Moreover, other applications include genetically modified crops and organisms, cell line engineering. The human stem cells segment is anticipated increase significantly, owing to the factors such as growing industry focus on stem cell research, increasing global awareness about stem cell therapies and rising funding from governments and private organizations.
Based on end-user, the CRISPR genome editing market is bifurcated into biotechnology companies, pharmaceutical companies and others. Likewise, others include academic research centers, research institutes etc. Among this the increasing prevalence of infectious diseases and cancer are driving the research and development activities and innovations worldwide; this is anticipated to drive the demand for genome editing in biotechnology & pharmaceutical companies in the next few years.
The CRISPR genome editing market report is studied across the key countries of North America, Europe, Asia Pacific and Rest of the World. Due to huge investments in genome editing research and development, well-developed healthcare infrastructure, and technological advancements, the North America region is projected to witness the largest market share in 2018. However, the Asia pacific region is expected to grow at a highest CAGR during the forecast period, owing to the Increasing government fund for research and development, increasing lifestyle-related disorders and rising disposable income.
Why to buy this report:
